MedTrace Logo

Quadratus Lumborum Block for Abdominoplasty

NCT02949778 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-12-19

No results posted yet for this study

Summary

Double blinded, randomized, controlled, phase IV intervention trial. Both groups will receive a quadratus lumborum Block (QL), using ropivacaine 3.75 mg/mL in the intervention group, and sterile sodium chloride in the control group. The aim of study is to investigate the effect of a QL Block on the perioperative pain during postbariatric abdominoplasty.

Conditions

  • Pain, Postoperative
  • Abdominoplasty

Interventions

PROCEDURE

QL-block

Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied

DRUG

Ropivacaine

Ropivacaine 3.75mg/ml administered in QL-block as active treatment

DRUG

Sodium Chloride

Sodium chloride 9mg/mL administered in QL-Block as placebo

Sponsors & Collaborators

  • Vestre Viken Hospital Trust

    lead OTHER

Principal Investigators

  • Thor Wilhelm Bjelland, MD, PhD · Vestre Viken HT, Baerum Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-07
Primary Completion
2017-06-15
Completion
2017-12-13

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02949778 on ClinicalTrials.gov